GlassScriptPhysician profile
Antonios N Wehbeh
NPI 1437564820
$1,157.78
in general payments reported to CMS, 2019-2025
15 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.87 · 2021: $109 · 2022: $146 · 2023: $220 · 2024: $87.38 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.93 | 2020-2025 | Rinvoq |
| Genzyme Corporation | $242.92 | 2022-2025 | |
| Ardelyx, INC. | $131.13 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $127.98 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $98.70 | 2020-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.41 | 2021-2025 | Xifaxan |
| Amgen INC. | $33.82 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $28.54 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $25.98 | 2020-2023 | Ocaliva |
| Mylan Institutional INC. | $25.47 | 2023 | Hulio |
| Lilly USA, LLC | $25.13 | 2024 | Omvoh |
| Mirum Pharmaceuticals, INC. | $19.54 | 2025 | Livmarli |
| Celgene Corporation | $16.80 | 2023 | Zeposia |
| Csl Behring | $14.23 | 2022 | |
| Gilead Sciences, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonios Wehbeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.